AstraZeneca and Algen Biotechnologies Partner for AI-Driven Gene-Editing Therapies

October 06, 2025
AstraZeneca has entered a $555 million partnership with Algen Biotechnologies to develop gene-editing therapies using AI and CRISPR technology.

AstraZeneca has signed a $555 million agreement with Algen Biotechnologies to advance AI-powered drug discovery in immunology, announced in a press release. This collaboration grants AstraZeneca exclusive rights to develop and commercialize therapies using Algen's CRISPR gene-editing technology.

Algen will leverage its AlgenBrain™ platform to identify novel therapeutic targets, focusing on immune system diseases. The platform integrates AI with high-throughput functional genomics to map disease progression and identify potential therapeutic targets. Algen is set to receive up to $555 million, contingent on achieving specific development, regulatory, and commercial milestones.

This partnership reflects a growing trend in the pharmaceutical industry to incorporate AI in drug development, aiming to enhance the discovery of new targets and improve the efficiency of drug development processes.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Life Sciences

10/06
Made Scientific and Streamline Bio Validate AI-Driven Robotics for Cell Therapy
10/06
Halia Therapeutics Appoints Paul Jones to Lead GENMOR-AI Platform
10/06
Heidi Secures $65 Million to Expand AI Healthcare Tool
10/06
Microsoft-Led Study Reveals AI-Crafted Toxins Evade DNA Screens
10/06
Embleema Secures $5M DoD Contract for Global Pathogen Detection

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Industry analysis

2025 Global Business Services Agenda: Gen AI Takes Center Stage

The Hackett Group

This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.

Read more

You May Also Like